Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

79.01EUR
16 Sep 2019
Change (% chg)

€-0.52 (-0.65%)
Prev Close
€79.53
Open
€78.91
Day's High
€79.40
Day's Low
€78.85
Volume
54,064
Avg. Vol
2,334,754
52-wk High
€82.11
52-wk Low
€71.74

Select another date:

Fri, Sep 13 2019

Novartis MS drug cuts relapse rate by half compared to Sanofi medicine

ZURICH, Sept 13 Novartis's investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in trials comparing it to Sanofi's Aubagio as the Swiss drugmaker aims to refresh its portfolio of medicines in neurological diseases.

Sanofi to pay Lexicon $260 million for terminated partnership

Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista.

Sanofi to pay Lexicon $260 million for terminated partnership

Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista.

Sanofi to pay Lexicon $260 mln for terminated partnership

Sept 10 Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista.

Novo Nordisk to cut insulin prices in the U.S.

COPENHAGEN Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly.

UPDATE 1-Novo Nordisk to cut insulin prices in the U.S.

COPENHAGEN, Sept 6 Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly.

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA , which sells a rival drug.

UPDATE 3-U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

Aug 28 A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.

U.S. judge rules for Sanofi in Amgen patent fight

Aug 28 A U.S. judge on Wendesday largely set aside a jury verdict that Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA. (Reporting by Jan Wolfe; editing by Jonathan Oatis)

Select another date: